-
17-10-2017, 11:38 AM
#181
VHT
Appendix 4C - quarterly On track for 200+% ARR
Highlights:
- Cash position NZ$9.29m
- Q2 FY18 Total Contract Value (TCV) NZ$2.32m, up 339% from NZ$528k in Q2
FY17
- Annual Recurring Revenue (ARR) NZ$2.14m at the end of Q2 FY18, up 94%
from NZ$1.1m at the end of FY17
- 25 SaaS customers signed to VolparaEnterpriseTM software, including
significant US “luminary sites”
-
23-10-2017, 11:34 PM
#182
VHT clearance in Taiwan Download Document 280.42KB
Sold half my BOT today in current meltup. Hope there is a good reason for it.
Last edited by Joshuatree; 23-10-2017 at 11:35 PM.
-
18-01-2018, 01:47 PM
#183
Has anyone looked at Polynovo, PNV, lately? Shareprice climbing steadily on encouraging news.
Disc: Not holding but interested.
-
25-01-2018, 05:18 PM
#184
Member
Originally Posted by showstring
CYP - Cynata Therapeutics is looking good at this price level. Feels like it might be ready for some upside.
Few recent independent research reports published with significantly higher share price targets. Potentially significant phase 1 clinical trial news expected towards end of year...
http://cynata.com/category/news/
DYOR
first batch of phase1 trial news is positive
stock getting some interest
still feel it should be a lot higher market cap than at present (easily 5x higher)
dyor
-
28-03-2018, 04:47 PM
#185
Member
More positive news and price action for CYP lately
15 Jan 2018 price was 58c
Current price today at 28 March 2018 is around $1.45
market cap still potentially small at $130m
no revenues yet etc, but tech looking very promising
-
10-05-2018, 11:41 AM
#186
MEB the mental health check app is now available and companies are using it, as diverse as Rio Tinto and the AFL rugby league.
Download Document 152.6KB
-
29-05-2018, 01:28 PM
#187
VHT great stuff s/p strong after 60c spp. 83.5c atm close to a new high. Sales ramping up big time.
2018 FINANCIAL RESULTS AND CAPITAL RAISE UPDATE
Highlights:
- Total revenue from contracts with customers up 53%
- Revenue from VolparaEnterprise customers up 1,945%
- Cash receipts from customers exceeded NZ$3m for the first time
- Gross margin has increased to 70%, up from 63% in FY17
- Net loss after tax improved 8%, reducing from NZ$9.6m in FY17 to NZ$8.8m in FY18
- Completion of a successful A$20 million capital raise
Wellington, NZ, 29th May 2018: Volpara Health Technologies (“Volpara”; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, has today released its full-year results for the financial year ended 31 March 2018.
The company has delivered strong year-on-year growth as a result of the successful transition, only begun in FY17, from a predominantly capital sales model to a Software as a Service (SaaS) model, as illustrated in the table below:
]SaaS revenue
Capital revenue
Service maintenance agreements revenue Other revenue
Total revenue
Total income, incl. grants
Gross margin percentage (%)
Net loss after taxes (NZ$’000’s)
Cash receipts from customers (NZ$’000’s)Total no. of VolparaEnterprise contracts signed Market share (No. & % of US women) (‘000’s) Annual Recurring Revenue (ARR) (NZ$’000’s) Total Contract Value (TCV) (NZ$’000’s)
FY18NZ$’000
1,902 575 304 31
2,812
3,535
70 (8,818) 3,068 57 1,297 (3.2%) 3,571 11,200
FY17NZ$’000
93 1,527 219 -1,839 2,047
63 (9,571) 2,270 14 294 (0.7%) 1,104 4,100
$ VarianceNZ$’000
1,809 (952) 85 31
973
1,488
7 753 798 43 1,003 2,467 7,100
% Variance
+1,945% -62% +39% +100%
+53%
+73%
+11% -8% +35% +307% +341% +223% +173%
]]Volpara CEO Dr Ralph Highnam said of the results: “These results reflect the tremendous progressthat has been made in FY18, where we met all our objectives, including increasing ARR by more than 200%, while keeping costs mostly in line with FY17 and increasing our market share to more than 3% of US women. It is pleasing to see our progress now beginning to be reflected in the financial results we are delivering.”
Cash on hand was NZ$4.84m as at 31 March 2018, and now is approx. NZ$24.5m after the successful placement and share purchase plan which has since raised A$20m for the Company.
“We have continued to develop VolparaEnterprise throughout FY18 while also making tremendous advances in our product pipeline, with some exciting new products set to be released to the market towards the end of the calendar year,” Dr Highnam said. “These products will help to ensure we have happy customers and at the same time draw more customers in and increase price per woman. With the successful capital raise, we now have the funds necessary to continue our strong growth, but as always we are still very much focused on preserving and improving shareholder value with prudent spending.”
Last edited by Joshuatree; 29-05-2018 at 01:31 PM.
-
29-05-2018, 08:27 PM
#188
Originally Posted by Joshuatree
MEB the mental health check app is now available and companies are using it, as diverse as Rio Tinto and the AFL rugby league.
Download Document 152.6KB
Thanks for the heads-up JT, interesting company. Have you looked into their competition and/or could you comment on their "moat" and competitive advantage beyond being pioneers?
Thanks! DH
Last edited by DarkHorse; 29-05-2018 at 09:25 PM.
-
29-05-2018, 10:06 PM
#189
No comment to make there DH.Am looking to take profits at some point, this has turned into a long trade partly due to my belief and partly to my lack of discipline(should have sold way back for a smaller gain and moved on) and yes competition will come or is already there.
Then again sold BOT too early and missed the stellar rise. sa la vie
-
30-05-2018, 09:09 PM
#190
Fair enough...same story with some of my smaller holdings...c'est la vie?
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks